A pure non-gestational ovarian choriocarcinoma with delayed solitary brain metastases: Case report and review of the literature

Introduction

Choriocarcinoma is a rare, highly malignant trophoblastic tumor with gestational or, rarely, germ cell origin.[1] Choriocarcinoma arising in the ovary can have either gestational or non-gestational origin. Gestational ovarian choriocarcinoma may arise in an ovarian pregnancy or represent metastases from intrauterine or intra-tubal primary disease.[2] Non-gestational ovarian choriocarcinoma (NGOC) is exceedingly rare and is usually mixed type associated with other germ cell tumors such as immature teratoma, endodermal sinus tumor, embryonal carcinoma and dysgerminoma.[3] Pure primary NGOC accounts for <1% of ovarian tumors. Non-gestational choriocarcinoma of the ovary has a worse prognosis compared to gestational choriocarcinoma.[4] We are reporting long-term follow-up rare case of pure NGOC with concurrent metastases to the spleen and adrenal glands, with delayed solitary brain metastases, 2 years after completion of primary treatment.

Case Report

A 26-year-old female patient (G1P1) presented with low back ache and vague abdominal pain for 1-month. There were no associated menstrual irregularities or abortions. She was evaluated for these complaints and found to have a right ovarian mass. She was further evaluated by Whole body Fludeoxyglucose positron emission tomography (FDG-PET) scan and CT scan vertex to mid thigh with oral and Intravenous contrast which revealed a lower abdominal mass [Figure 1] with splenic and right adrenal lesions suggestive of metastases [Figure 2]. Increased FDG concentrations were noted in all these lesions. There was no abnormal uptake in the brain or other organs. Her human chorionic gonadotropin (HCG) level was elevated and was 8160 IU/mL. With these findings, she was suspected to have NGOC with ovarian tumor excision (right salpingo-oophorectomy) with partial omentectomy, partial splenectomy and right adrenalectomy in December 2010. Histopathology of the specimen showed pure non-gestational choriocarcinoma. This was, followed by six cycles of chemotherapy with bleomycine, etoposide and vincristine. She was on regular follow-up with HCG levels, which came down to 4.6 IU/ml.

Close

Figure 1

Computed tomogram pelvis with oral and intravenous contrast showing lower abdominal mass as shown by an arrow

Export to PPT

Close

Figure 2

Computed tomogram abdomen with oral and intravenous contrast showing right adrenal and splenic metastases as shown by arrows

Export to PPT

After 2 years of treatment, she presented back to us with a headache, vomitings of 2 months duration and generalized tonic clonic seizures for 10 days. She had papilledema without any motor or sensory deficits. She was evaluated with computed tomogram (CT) of the head that revealed an iso to hyperdense mass lesion with perilesional edema in the left frontal lobe with enhancement on contrast [Figure 3]. There was mass effect and subfalcine herniation. Magnetic resonance imaging of the head revealed a single left superior frontal gyrus solitary mass lesion measuring 3 cm × 3.3 cm × 3.8 cm, which was isointense on T1-Weighted and hyperintense on T2-Weighted images with significant perilesional edema. The lesion was heterogeneously enhancing on contrast. Her serum beta HCG level shot up to 1099 mIU/ml and cancer antigen – 125 levels was 19–71 IU/ml. Chest X-ray was normal. She underwent left frontal craniotomy and total excision of the lesion. Postoperative CT head revealed complete excision of the lesion. She recovered gradually and was discharged. Histopathology revealed metastatic choriocarcinoma [Figure 4]. She underwent radiotherapy of the brain with 18 Gy in 10 fractions. Post-radiotherapy the HCG level came down to 12 IU/mL. At 14 months follow-up, patient was asymptomatic with no seizures. Beta HCG level was < IU/mL. Chest X-ray and ultrasound abdomen was within normal levels. Follow-up CT scan showed no recurrence of the lesion [Figure 5].

Close

Figure 3

Computed tomogram brain contrast showing single metastasis

Export to PPT

Close

Figure 4

Microphotographs reveal cellular neoplasm with plump tumor cells in broad trabeculae separated by zones of hemorrhage and necrosis (a). The tumors cells are strongly labeled by cytokeratin (a, inset). There are several bizarre tumor giant cells seen (b, arrow). ([a] H and E, inset: Cytokeratin immunochemistry; [b] H and E) (magnification = scale bar)

Export to PPT

Close

Figure 5

Postoperative computed tomogram contrast at the end of 1-year showing no recurrence

Export to PPT

Discussion

Choriocarcinoma is a malignant gestational trophoblastic disease, which commonly (50%) occurs after hydatidiform mole. It can occur after a spontaneous abortion in 25% of cases and after the normal pregnancy in 22.5%.[15] Rarely, it may follow ectopic pregnancy and may arise from the ovaries. The tumor is characterized by the presence of two cell lines: The cytotrophoblast, the cells of which lie in sheets to form villus-like structures, and the syncytiotrophoblast, which secretes beta-human chorionic gonadotropin and human placental lactogen and is seen at the advancing edge of the tumor.[6] Most of the primary non-gestational choriocarcinoma of ovary occurs in admixture with teratoma, endodermal sinus tumor, embryonal carcinoma or dysgerminoma.[7] Distinction of non-gestational choriocarcinoma from gestational choriocarcinoma is impossible on the histomorphology unless an evidence of pregnancy or other germ cell neoplasm is encountered. DNA polymorphism analysis using two or three appropriate VNTR loci from the tumor and the patient for identification of paternal sequences establishes the diagnosis of gestational or non-gestational choriocarcinoma.[78]

Ovarian choriocarcinoma with concurrent metastases to spleen and adrenal gland undergoing successful treatment is extremely rare, and this is the only one case, reported in the literature.[5] The tumor has a marked tendency to metastasize early by blood-borne dissemination, to the lungs (80%), pelvis (20%), vagina (30%), liver (10%) and other rare sites including gastrointestinal tract, spleen and kidney. The central nervous system is seldom involved in the absence of pulmonary metastases.[6] About 10% of choriocarcinoma metastases to the brain and is a leading cause of death.[9] Exact incidence of NGOC metastasis to the brain is unknown. The metastasis is commonly hemorrhagic because of the innate capacity of trophoblastic cells to invade and erode vessel walls.[6] In our case, patient presented with concurrent metastases to spleen and adrenal gland and underwent optimal debulking. The patient also received a complete course of chemotherapy. In spite of that, the patient had delayed solitary brain metastases 2 years after completion of chemotherapy, suggestive of aggressive behavior of the tumor.

The treatment of choriocarcinoma consists of polychemotherapy, including regimens that have generally shown to be beneficial with acceptable cure rates and low recurrences. Triple agent chemotherapy is recommended in high risk cases with multiple distant metastases to the liver, lungs or central nervous system, postterm gestational trophoblastic disease and pretreatment serum HCG levels >40,000 mIU/ml or interval of > 4 months since pregnancy.[210] Extreme rarity of non-gestational choriocarcinoma hinders therapeutic considerations. However, triple agent chemotherapy has been advocated strongly in these cases, in view of associated poor prognosis.[15] Cerebral metastases may present while on treatment or as a relapse after partial remission. Metastasis to the brain is considered as a poor prognostic indicator. Beta-HCG is the good predictive indicator of prognosis and recurrence.

Conclusion

Non-gestational ovarian choriocarcinoma with concurrent metastases to spleen, adrenal is an extremely rare occurrence and is a very aggressive tumor. Despite aggressive management of primary disease, prognosis is poor. Complete excision of the intracranial tumor, followed by chemotherapy and radiotherapy may prolong the survival. A long follow-up with regular beta HCG level estimation is advised to deal with the risk of delayed metastases even when the primary has been well controlled.